These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 8261581)

  • 1. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
    Treskes M; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
    Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
    Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
    Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
    Schuchter LM
    Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V; Giles FJ
    Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
    Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
    Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
    Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
    Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
    Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
    Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
    Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
    Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative adverse effect profiles of platinum drugs.
    McKeage MJ
    Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
    Gandara DR; Wiebe VJ; Perez EA; Makuch RW; DeGregorio MW
    Crit Rev Oncol Hematol; 1990; 10(4):353-65. PubMed ID: 2177606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
    Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
    Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
    Santini V
    Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
    Links M; Lewis C
    Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
    Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
    Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
    van der Vijgh WJ; Korst AE
    Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of carboplatin.
    van der Vijgh WJ
    Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [About side effects of platinum drugs].
    Waszkiewicz K
    Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.